A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia (clinicaltrials.gov) - Sep 24, 2026 - P1/2 | N=68 | Recruiting | Sponsor: Eli Lilly and Company | Trial primary completion date: May 2028 ➔ Feb 2028
Trial primary completion date • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura
|